IDEAYA Biosciences’ (IDYA) “Outperform” Rating Reiterated at Royal Bank Of Canada

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report)‘s stock had its “outperform” rating restated by analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $45.00 price objective on the stock. Royal Bank Of Canada‘s price target suggests a potential upside of 51.66% from the stock’s previous close.

A number of other research firms have also weighed in on IDYA. Citizens Jmp reaffirmed a “market outperform” rating and set a $42.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, September 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Thursday, October 15th. Wedbush boosted their target price on IDEAYA Biosciences from $60.00 to $63.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 4th. Jefferies Financial Group restated a “buy” rating on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Finally, Guggenheim reduced their price target on IDEAYA Biosciences from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Wednesday, November 4th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $49.55.

View Our Latest Research Report on IDYA

IDEAYA Biosciences Price Performance

Shares of IDYA stock opened at $29.67 on Tuesday. The firm has a market cap of $2.87 billion, a PE ratio of -6.98 and a beta of 0.08. The company has a 50-day moving average of $35.28 and a two-hundred day moving average of $33.88. IDEAYA Biosciences has a 1-year low of $26.81 and a 1-year high of $42.68.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.04). IDEAYA Biosciences had a negative return on equity of 39.78% and a negative net margin of 1,157.18%. The firm had revenue of $10.24 million for the quarter, compared to analysts’ expectations of $7.58 million. During the same quarter in the prior year, the business earned $1.33 earnings per share. The company’s quarterly revenue was up 14.6% on a year-over-year basis. Sell-side analysts anticipate that IDEAYA Biosciences will post -4.63 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Yujiro Hata sold 26,338 shares of IDEAYA Biosciences stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total transaction of $985,304.58. Following the sale, the chief executive officer directly owned 690,695 shares in the company, valued at $25,838,899.95. This trade represents a 3.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On IDEAYA Biosciences

Several large investors have recently modified their holdings of the company. Aquatic Capital Management LLC lifted its holdings in shares of IDEAYA Biosciences by 3,154.0% during the third quarter. Aquatic Capital Management LLC now owns 45,361 shares of the company’s stock worth $1,743,000 after purchasing an additional 43,967 shares during the period. Goldman Sachs Group Inc. increased its stake in IDEAYA Biosciences by 18.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,453,997 shares of the company’s stock valued at $55,863,000 after buying an additional 222,383 shares during the period. Jump Financial LLC increased its stake in IDEAYA Biosciences by 326.4% in the 3rd quarter. Jump Financial LLC now owns 239,240 shares of the company’s stock valued at $9,192,000 after buying an additional 183,131 shares during the period. Aberdeen Group plc raised its position in IDEAYA Biosciences by 5.3% during the 3rd quarter. Aberdeen Group plc now owns 590,777 shares of the company’s stock worth $22,698,000 after buying an additional 29,843 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in IDEAYA Biosciences by 96.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 100,855 shares of the company’s stock worth $3,875,000 after buying an additional 49,596 shares during the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

About IDEAYA Biosciences

(Get Free Report)

IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.

Recommended Stories

Analyst Recommendations for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.